A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death

被引：10

作者：

Ray, Arghya ^{[1
,2
]}

Du, Ting ^{[1
,2
]}

Wan, Xueping ^{[1
,2
]}

Song, Yan ^{[1
,2
]}

Pillai, Sindhu C. ^{[1
,2
]}

Musa, Md. Abu ^{[1
,2
]}

Fang, Teng ^{[1
,2
]}

Moore, Jared ^{[3
]}

Blank, Brian ^{[3
]}

Du, Xiaohui ^{[3
]}

Chen, Xi ^{[3
]}

Warne, Robert ^{[3
]}

Sutimantanapi, Dena ^{[3
]}

Lui, Fang ^{[3
]}

Zavorotinskaya, Tatiana ^{[3
]}

Colas, Christophe ^{[3
]}

Friedman, Lori ^{[3
]}

Junttila, Melissa R. ^{[3
]}

Chauhan, Dharminder ^{[1
,2
]}

Anderson, Kenneth C. ^{[1
,2
]}

机构：

[1] Harvard Med Sch, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA

[2] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA

[3] ORIC Pharmaceut Inc, South San Francisco, CA USA

来源：

BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期

基金：

美国国家卫生研究院;

关键词：

T-CELLS; COMBINATION; CHECKPOINT; ADENOSINE; CANCER;

D O I：

10.1038/s41408-024-01019-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

center dot CD73 is the key ectoenzyme involved in the generation of AMP-derived adenosine, which contributes to immunosuppression in the MM BM milieu. center dot Blocking CD73 activity with a potent, selective, orally bioavailable CD73 inhibitor ORIC-533 decreases adenosine generation, overcomes immune suppression, and restores immune cell-mediated MM cell lysis. center dot Based on these preclinical studies, a multi-center clinical trial of ORIC-533 has been initiated in patients with relapsed refractory MM (NCT05227144).

引用

页数：6

共 25 条

[1] Promise of Immune Therapies in Multiple Myeloma [J].

Anderson, Kenneth C. .

JOURNAL OF ONCOLOGY PRACTICE, 2018, 14 (07) :411-+

[2]

[Anonymous], 2021, Key Statistics About Multiple Myeloma

[3] Immunity, inflammation and cancer: a leading role for adenosine [J].

Antonioli, Luca ;

Blandizzi, Corrado ;

Pacher, Pal ;

Hasko, Gyoergy .

NATURE REVIEWS CANCER, 2013, 13 (12) :842-857

[4] Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial [J].

Buisseret, L. ;

Pommey, S. ;

Allard, B. ;

Garaud, S. ;

Bergeron, M. ;

Cousineau, I. ;

Ameye, L. ;

Bareche, Y. ;

Paesmans, M. ;

Crown, J. P. A. ;

Di Leo, A. ;

Loi, S. ;

Piccart-Gebhart, M. ;

Willard-Gallo, K. ;

Sotiriou, C. ;

Stagg, J. .

ANNALS OF ONCOLOGY, 2018, 29 (04) :1056-1062

[5] Inhibition of Histone Deacetylase (HDAC) Enhances Checkpoint Blockade Efficacy by Rendering Bladder Cancer Cells Visible for T Cell-Mediated Destruction [J].

Burke, Brianna ;

Eden, Catherine ;

Perez, Cynthia ;

Belshoff, Alex ;

Hart, Spencer ;

Plaza-Rojas, Lourdes ;

Delos Reyes, Michael ;

Prajapati, Kushal ;

Voelkel-Johnson, Christina ;

Henry, Elizabeth ;

Gupta, Gopal ;

Guevara-Patino, Jose .

FRONTIERS IN ONCOLOGY, 2020, 10

[6] Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients [J].

Busch, A. ;

Zeh, D. ;

Janzen, V. ;

Muegge, L. -O. ;

Wolf, D. ;

Fingerhut, L. ;

Hahn-Ast, C. ;

Maurer, O. ;

Brossart, P. ;

von Lilienfeld-Toal, M. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 177 (02) :439-453

[7] Adenosinergic Signaling Alters Natural Killer Cell Functional Responses [J].

Chambers, Andrea M. ;

Wang, Jiao ;

Lupo, Kyle B. ;

Yu, Hao ;

Lanman, Nadia M. Atallah ;

Matosevic, Sandro .

FRONTIERS IN IMMUNOLOGY, 2018, 9

[8] Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target [J].

Chauhan, Dharminder ;

Singh, Ajita V. ;

Brahmandam, Mohan ;

Carrasco, Ruben ;

Bandi, Madhavi ;

Hideshima, Teru ;

Bianchi, Giada ;

Podar, Klaus ;

Tai, Yu-Tzu ;

Mitsiades, Constantine ;

Raje, Noopur ;

Jaye, David L. ;

Kumar, Shaji K. ;

Richardson, Paul ;

Munshi, Nikhil ;

Anderson, Kenneth C. .

CANCER CELL, 2009, 16 (04) :309-323

[9] The Multifaceted Actions of CD73 During Development and Suppressive Actions of Regulatory T Cells [J].

Da, Meihong ;

Chen, Luxia ;

Enk, Alexander ;

Ring, Sabine ;

Mahnke, Karsten .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[10] Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma [J].

Goerguen, Guellue ;

Samur, Mehmet K. ;

Cowens, Kristen B. ;

Paula, Steven ;

Bianchi, Giada ;

Anderson, Julie E. ;

White, Randie E. ;

Singh, Ahaana ;

Ohguchi, Hiroto ;

Suzuki, Rikio ;

Kikuchi, Shohei ;

Harada, Takeshi ;

Hideshima, Teru ;

Tai, Yu-Tzu ;

Laubach, Jacob P. ;

Raje, Noopur ;

Magrangeas, Florence ;

Minvielle, Stephane ;

Avet-Loiseau, Herve ;

Munshi, Nikhil C. ;

Dorfman, David M. ;

Richardson, Paul G. ;

Anderson, Kenneth C. .

CLINICAL CANCER RESEARCH, 2015, 21 (20) :4607-4618

← 1 2 3 →